Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

GLP-1s appear safe for treating diabetes in pregnancy, but evidence gaps remain (opens in a new tab)

medicalxpress.com · 2026-09-30

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3

The source study

Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement

The Lancet Obstetrics, Gynaecology, & Women's Health · 2026
Open source record (opens in a new tab)
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement

    The Lancet Obstetrics, Gynaecology, & Women's Health · 2026

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement

    Where the story links (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 7Not checkedNew research to be presented at EASD and published in The Lancet Obstetrics, Gynaecology & Women's Health says GLP-1 receptor agonist drugs for diabetes and weight management in women living with diabetes are not associated with adverse pregnancy outcomes in most cases.View evidenceHide evidence

As statednot associated with adverse pregnancy outcomes in most cases

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 7Not checkedThe findings are based on a systematic review and meta-analysis of available studies, using seven studies with more than 43,000 participants exposed to GLP-1 RAs.View evidenceHide evidence

As statedseven studies; more than 43,000 participants

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 7Not checkedThe meta-analysis suggested no significant associations between GLP-1 RA exposure and preterm birth, stillbirth, neonatal death, cesarean section, pregnancy hypertensive disorders or preeclampsia, or small-for-gestational-age infant.View evidenceHide evidence

As statedno significant associations

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 7Not checkedEarly pregnancy loss (<14–22 weeks), including miscarriage or termination, was 31% more common among exposed women, but the article says this finding is difficult to interpret because miscarriage and deliberate termination were counted together in the main study representing most participants.View evidenceHide evidence

As stated31% more common

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 7Not checkedThe authors and consensus panel say evidence remains limited for miscarriage, exposure beyond the first trimester, postpartum use, breastfeeding, and long-term maternal and offspring outcomes, and they call for more prospective studies.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 7Not checkedThe consensus recommendations supported GLP-1 RA use for preconception metabolic health optimization where needed in women with type 2 diabetes, while recognizing potential benefits in women with type 1 diabetes and previous gestational diabetes but noting direct evidence is limited.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 7 of 7Not checkedThe article says available lactation data suggest subcutaneously administered GLP-1 RAs are undetectable or present at negligible concentrations in breast milk, but clinical safety data for breastfed infants remain insufficient, especially for oral formulations.View evidenceHide evidence

As statedundetectable or negligible concentrations

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement

The Lancet Obstetrics, Gynaecology, & Women's Health · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 41 candidate papers

Selected

Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement

The Lancet Obstetrics, Gynaecology, & Women's Health · 2026 · Crossref

Source (opens in a new tab)
Candidate

Perinatal mental health care must reach women before crisis

The Lancet Obstetrics, Gynaecology, & Women's Health · 2026 · Crossref

Source (opens in a new tab)
Candidate

María-Trinidad Herrero-Ezquerro: advocating for women in neurological research

The Lancet Obstetrics, Gynaecology, & Women's Health · 2026 · Crossref

Source (opens in a new tab)

And 35 more candidates considered.